Expert Guidance to Optimize Therapy Decisions for Advanced Melanoma
  • CME
  • CE

In this interactive, CME/CE-certified module, review practical guidance and the most recent data informing optimal treatment strategies for advanced melanoma.
Michael Postow, MD
Program Director
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Pharmacists: 1.5 contact hours (0.15 CEUs)
Released: January 3, 2019 Expiration: January 2, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Participate in multidisciplinary decision making for patients with metastatic melanoma based on available data, treatment guidelines, and expert recommendations
  • Plan optimal adjuvant treatment strategies for patients with melanoma at high risk of recurrence after surgical resection based on available data and expert recommendations
  • Manage adverse events effectively in patients receiving novel targeted agents or immunotherapies for melanoma based on available data and recommendations
  • Counsel patients to understand their treatment options and to be proactive, knowledgeable participants in their care

Acknowledgements

Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Produced in collaboration with
Grace Logo
This activity is supported by educational grants from
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Michael Postow, MD

Assistant Attending Physician
Melanoma and Immunotherapeutics Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Michael Postow, MD, has disclosed that he has received consulting fees from Aduro, Array, Bristol-Myers Squibb, Incyte, Merck, New Link Genetics, and Novartis; fees for non-CME/CE services from Bristol-Myers Squibb and Merck; and funds for research support from Array, AstraZeneca, Bristol-Myers Squibb, Infinity, Merck, Novartis, and RGenix.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Joy Curzio

Editorial Contributor

Joy Curzio has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with melanoma.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians to plan optimal therapy for their patients with advanced melanoma.

Physician Continuing Medical Education

Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-490-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 03, 2019, through January 02, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Tanios Bekaii-Saab, MD, FACP, on which patients are most likely to benefit from later-line checkpoint inhibitors for advanced gastric/GEJ cancers

Tanios Bekaii-Saab Tanios Bekaii-Saab, MD, FACP Released: July 18, 2019

Drs. Todd M. Bauer, Giuseppe Giaccone, Axel Grothey, John L. Marshall, and Michael J. Pishvaian discuss the latest data on 10 key clinical biomarkers in solid tumors.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Giuseppe Giaccone, MD, PhD Axel Grothey Headshot Axel Grothey, MD Michael J. Pishvaian, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: July 11, 2019 Expiration: July 10, 2020

Review key points for using immune checkpoint inhibitors for treating head and neck cancers (HNSCC) with this downloadable resource guide.

Barbara Ann Burtness, MD
Program Director
Released: June 25, 2019

Review this CME-certified Webcast of a Clinical Care Options symposium, in which experts discuss adjuvant and neoadjuvant immunotherapy for melanoma.

Michael Atkins Headshot Michael B. Atkins, MD
Program Director
Rodabe Amaria, MD Ahmad Tarhini, MD, PhD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits Released: June 21, 2019 Expiration: June 20, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?